ES2167717T3 - Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos. - Google Patents

Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos.

Info

Publication number
ES2167717T3
ES2167717T3 ES97908655T ES97908655T ES2167717T3 ES 2167717 T3 ES2167717 T3 ES 2167717T3 ES 97908655 T ES97908655 T ES 97908655T ES 97908655 T ES97908655 T ES 97908655T ES 2167717 T3 ES2167717 T3 ES 2167717T3
Authority
ES
Spain
Prior art keywords
amino acids
pharmaceutical agents
acids replaced
new
cyclical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97908655T
Other languages
English (en)
Spanish (es)
Inventor
David Christopher Horwell
Justin S Bryans
Clare O Kneen
Andrew I Morrell
Giles S Ratcliffe
Johannes Hartenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2167717T3 publication Critical patent/ES2167717T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES97908655T 1996-03-14 1997-02-18 Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos. Expired - Lifetime ES2167717T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1343296P 1996-03-14 1996-03-14

Publications (1)

Publication Number Publication Date
ES2167717T3 true ES2167717T3 (es) 2002-05-16

Family

ID=21759938

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97908655T Expired - Lifetime ES2167717T3 (es) 1996-03-14 1997-02-18 Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos.

Country Status (29)

Country Link
US (1) US6103932A (enExample)
EP (1) EP0888286B1 (enExample)
JP (1) JP2000506861A (enExample)
KR (1) KR100512506B1 (enExample)
AT (1) ATE207878T1 (enExample)
AU (1) AU734173B2 (enExample)
BG (1) BG63662B1 (enExample)
BR (1) BR9708200A (enExample)
CA (1) CA2244912C (enExample)
CZ (1) CZ293759B6 (enExample)
DE (1) DE69707842T2 (enExample)
DK (2) DK0888286T3 (enExample)
EA (1) EA002765B1 (enExample)
EE (1) EE9800309A (enExample)
ES (1) ES2167717T3 (enExample)
GE (1) GEP20012413B (enExample)
HU (1) HU224720B1 (enExample)
IL (1) IL125544A (enExample)
IS (1) IS1990B (enExample)
MX (1) MX9806069A (enExample)
NO (1) NO984205L (enExample)
NZ (1) NZ331143A (enExample)
PL (1) PL185991B1 (enExample)
PT (1) PT888286E (enExample)
SK (1) SK283295B6 (enExample)
TR (1) TR199801807T2 (enExample)
UA (1) UA49011C2 (enExample)
WO (1) WO1997033858A1 (enExample)
ZA (1) ZA972200B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
ATE323067T1 (de) 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
NZ503963A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
PL345340A1 (en) 1998-07-09 2001-12-17 Warner Lambert Co Compositions comprising gaba analogs and caffeine
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
HRP20010581A2 (en) * 1999-12-08 2002-08-31 Warner Lambert Co Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
AU2001247762A1 (en) * 2000-03-28 2001-10-08 Delorenzo, Robert, J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
DE10048715A1 (de) * 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6683112B2 (en) * 2000-10-24 2004-01-27 Andrx Corporation Gabapentin prodrugs and formulations
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
JP2004530637A (ja) 2000-11-02 2004-10-07 テバ ファーマシューティカル インダストリーズ リミティド ガバペンチン中間体の製造のための改善方法
US20040063994A1 (en) * 2001-03-16 2004-04-01 Paolo Rossi Process for the preparation of cyclic amino acids
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20050209332A1 (en) * 2004-03-17 2005-09-22 Hikal Limited Gabapentin analogues and process thereof
WO2005087709A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
US7632864B2 (en) * 2004-03-17 2009-12-15 Hikal Ltd. Gabapentin analogues and process thereof
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
CA2710538A1 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
US9192681B2 (en) 2009-02-24 2015-11-24 Nektar Therapeutics Oligomer-amino acid conjugates
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014113717A1 (en) 2013-01-18 2014-07-24 Ark Diagnostics, Inc. Voriconazole immunoassays
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
WO2014126861A1 (en) 2013-02-13 2014-08-21 Ark Diagnostics, Inc. Posaconazole immunoassays
JP7441181B2 (ja) 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク． ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2543821C2 (de) * 1974-12-21 1984-10-18 Gödecke AG, 1000 Berlin Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
DE2626467C2 (de) * 1976-06-12 1984-11-22 Gödecke AG, 1000 Berlin 1-(N-Isopropylaminomethyl)-cyclohexanessigsäure, Verfahren zu deren Herstellung und diese Verbindung enthaltende Arzneimittel
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5098931A (en) * 1989-08-31 1992-03-24 Merck & Co., Inc. 7-substituted HMG-CoA reductase inhibitors
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
TW201738B (enExample) * 1990-03-20 1993-03-11 Sanofi Co
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
FR2691146B1 (fr) * 1992-05-15 1998-01-02 Adir Nouveaux derives d'acides alcenecarboxyliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic

Also Published As

Publication number Publication date
EE9800309A (et) 1999-02-15
IS1990B (is) 2005-02-15
US6103932A (en) 2000-08-15
DK0888286T3 (da) 2002-02-18
GEP20012413B (en) 2001-04-25
NO984205L (no) 1998-09-14
BR9708200A (pt) 1999-07-27
EA199800798A1 (ru) 1999-04-29
TR199801807T2 (xx) 1998-12-21
SK123898A3 (en) 2000-04-10
EP0888286B1 (en) 2001-10-31
BG63662B1 (bg) 2002-08-30
CA2244912A1 (en) 1997-09-18
ATE207878T1 (de) 2001-11-15
DE69707842D1 (de) 2001-12-06
WO1997033858A1 (en) 1997-09-18
UA49011C2 (uk) 2002-09-16
BG102733A (en) 1999-04-30
NO984205D0 (no) 1998-09-11
KR100512506B1 (ko) 2005-12-21
HUP9902136A3 (en) 2000-03-28
CA2244912C (en) 2005-07-12
DE69707842T2 (de) 2002-05-16
PL328816A1 (en) 1999-02-15
EP0888286A1 (en) 1999-01-07
PT888286E (pt) 2002-04-29
CZ286398A3 (cs) 1999-03-17
IL125544A (en) 2002-03-10
ZA972200B (en) 1997-09-17
CZ293759B6 (cs) 2004-07-14
AU734173B2 (en) 2001-06-07
MX9806069A (es) 1998-11-30
PL185991B1 (pl) 2003-09-30
HUP9902136A2 (hu) 1999-10-28
EA002765B1 (ru) 2002-08-29
NZ331143A (en) 2001-06-29
DK0888285T3 (da) 2002-04-08
HU224720B1 (en) 2006-01-30
JP2000506861A (ja) 2000-06-06
AU2051197A (en) 1997-10-01
IL125544A0 (en) 1999-03-12
IS4819A (is) 1998-08-10
KR19990087756A (ko) 1999-12-27
SK283295B6 (sk) 2003-05-02

Similar Documents

Publication Publication Date Title
ES2176668T3 (es) Aminoacidos ciclicos novedosos como agentes farmaceuticos.
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
CR6392A (es) Moduladores de ccr5
GT199700009AA (es) Terapia combinada para la osteoporosis
GT199800046A (es) Compuestos de pirazina.
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
EA199800798A1 (ru) Новые замешенные циклические аминокислоты в качестве фармацевтических агентов
PA8452701A1 (es) Agonistas de prostaglandinas
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
ES2255063T3 (es) Inmunomodulador de polisacaridos capsular.
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
PT998287E (pt) Utilizacao de levobupivacaina
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
BR9809650A (pt) Composição oral para remineralização dos dentes, e, processo para remineralizar porções desmineralizadas das estruturas de dentes
MX9704490A (es) Tratamiento terapeutico combinado de las patologias hiperproliferativas.
DK0825865T3 (da) Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2184300T3 (es) Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
BR9808226A (pt) Coronavìrus respiratório bovino como uma vacina